We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Online Cancer Database Speeds Drug Discovery Process

By LabMedica International staff writers
Posted on 16 Dec 2010
Print article
A powerful new cancer drug-discovery database has been launched to speed up the process of bringing drugs from the research bench to point-of-care.

The Cancer Research UK-funded database--known as canSAR--has been set up by researchers at Cancer Research UK's Center for Cancer Therapeutics at The Institute of Cancer Research (ICR; London) to create a one-stop-shop for scientists worldwide. For the first time, it brings together all the relevant biological, chemical, pharmacological, and eventually clinical data about important genes and proteins in every type of cancer in a way that greatly aids the discovery of new drugs.

The freely available database allows scientists and clinicians to search through cancer-related data and information across the spectrum of research--from genomics to clinical trials--in a portion of the time it would earlier have taken them to collected this information.

Dr. Bissan Al-Lazikani, an ICR scientist who led the research team that developed canSAR, stated, "With the unprecedented amounts of electronic data being generated by modern molecular research techniques, the demand for a resource that brings together all this information and makes it available in a clear and manageable format is greater than ever. Previously the information was stored in many different locations and formats, which limited its effective use by researchers.”

Prof. Paul Workman, director of the Cancer Research UK Center for Cancer Therapeutics at the ICR, said, "We have already found canSAR to be fantastically useful in our own cancer drug discovery research. We are applying it to evaluate large number of potential drug targets in a faster and more systematic way than before and to select the best ones to work on. Having road tested it ourselves, I'm really excited about our powerful canSAR tool and I'm delighted to make it available to the cancer research community worldwide. Scientists can now, at the click of a button and at a single online location, rapidly identify the biological and structural characteristics of an actual or potential drug target, find the genes and proteins that it interacts with, assess its structural drugability and identify any small molecule chemical inhibitors. Researchers can also find information on the cancer cell lines that are most suitable for their experiments. This information is now available in minutes whereas it would previously have taken weeks to find.”

canSAR contains information on the entire human proteome--the protein equivalent of the human genome--as well as linking to data on more than 1,000 cancer cells lines, utilized by researchers to study the effect of new drugs in the lab. Significantly, scientists will also have improved access to information about all the chemical compounds known to be active on a particular drug target--tying the biology and chemistry together in a new way.

"For example, one can quickly look at data on 700,000 chemical compounds acting on 4,000 molecular targets. It contains a total of more than eight million experimental data points. Patients will benefit because researchers will be able to move more quickly from a basic research discovery to new drugs in the clinic,” added Prof. Workman.

Dr. Lesley Walker, Cancer Research UK's director of cancer information, said, "This new database will provide scientists with easy access to research being carried out by other specialist groups around the world, paving the way for a much more collaborative way of working. Hopefully, this will help accelerate the pace at which discoveries involving the nuts and bolts of cancer can be translated into effective new drugs in the clinic. I'd encourage all researchers to take advantage of this important resource.”

canSAR v1.0 can be accessed online (please see Related Links below), and is an integrated database and workbench that brings together biologic, chemical, pharmacologic (and ultimately clinical), data. Its goal is to integrate this information and make it accessible to cancer research scientists from multiple disciplines worldwide, in order to help with hypothesis generation in cancer research, and support drug discovery decisions.

Users can search canSAR using text queries, protein/gene name searches, any keyword searches, chemical structure searches, and sequence similarity searches. Moreover, users can explore and filter chemical compound sets, view experimental data, and produce summary plots.

Related Links:

Cancer Research UK
canSAR v1.0



New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Quantitative Immunoassay Analyzer
AS050
New
Silver Member
Static Concentrator
BJP 10

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.